logo
Macron sues US influencer over ‘global humiliation' of claims wife is a man

Macron sues US influencer over ‘global humiliation' of claims wife is a man

The Macrons said in a complaint filed in Delaware Superior Court that Owens has waged a lie-filled "campaign of global humiliation" to promote her podcast and expand her "frenzied" fan base.
These lies included that Brigitte Macron, 72, was born under the name Jean-Michel Trogneux, the actual name of her older brother, the Macrons said. "Owens has dissected their appearance, their marriage, their friends, their family, and their personal history � twisting it all into a grotesque narrative designed to inflame and degrade," the complaint said.
"The result," the complaint added, "is relentless bullying on a worldwide scale." In her podcast
, Owens said, "This lawsuit is littered with factual inaccuracies," and part of an "obvious and desperate public relations strategy" to smear her character.
Owens also said she did not know a lawsuit was coming, though lawyers for both sides had been communicating since January.
A spokesperson for Owens called the lawsuit itself an effort to bully her, after Brigitte Macron rejected Owens' repeated requests for an interview.
"This is a foreign government attacking the First Amendment rights of an American independent journalist," the spokesperson said. In a joint statement released by their lawyers, the Macrons said they sued after Owens rejected three demands that she retract defamatory statements.
"Ms. Owens's campaign of defamation was plainly designed to harass and cause pain to us and our families and to garner attention and notoriety," the Macrons said. "We gave her every opportunity to back away from these claims, but she refused."
The lawsuit is a rare case of a world leader suing for defamation.
President Donald Trump has also turned to the courts, including in a $10 billion lawsuit accusing The Wall Street Journal of defaming him by claiming he created a lewd birthday greeting for disgraced late financier Jeffrey Epstein in 2003.
The Journal said it would defend against that case and had full confidence in its reporting. In December, meanwhile, Trump reached a $15 million settlement with Walt Disney-owned ABC over an inaccurate claim that a jury found him liable for rape, rather than sexual assault, in a civil lawsuit.
To prevail in U.S. defamation cases, public figures must show defendants engaged in "actual malice," a tough legal standard requiring proof the defendants knew what they published was false or had reckless disregard for its truth.
Owens has more than 6.9 million followers on X and more than 4.5 million YouTube subscribers.
The Macrons' lawsuit focuses on the eight-part podcast "Becoming Brigitte," which has more than 2.3 million views on YouTube, and X posts linked to it. According to the Macrons, the series spread "verifiably false and devastating lies," including that Brigitte Macron stole another person's identity and
transitioned to female, and that the Macrons are blood relatives committing incest. The complaint discusses circumstances under which the Macrons met, when the now 47-year-old president was a high school student and Brigitte was a teacher. It said their relationship "remained within the bounds of the law."
According to the complaint, baseless speculation about Brigitte Macron's gender began surfacing in 2021, and the topic has been discussed on popular podcasts hosted by Tucker Carlson and Joe Rogan, who have many conservative followers.
In September, Brigitte won a lawsuit in a French court against two women, including a self-described medium, who contributed to spreading rumours about her gender.
An appeals court overturned that decision this month, and Brigitte Macron has appealed to France's highest court.
The case is Macron et al v Owens et al, Delaware Superior Court, No. N25C-07-194.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Book review: Downfall of last shah of Iran
Book review: Downfall of last shah of Iran

Irish Examiner

time4 hours ago

  • Irish Examiner

Book review: Downfall of last shah of Iran

Written with the galloping pace of a cliff-edge political thriller and the intimacy of a memoir, Scott Anderson's King of Kings is a wonderful, engaging history. It is a tremendous summation of the clichés that can attend the end, benign or otherwise, of a regime that imagined itself loved and secure. It is also a warning to those prepared today to see our own times through the prism offered by a resonating episode from the past. Mohammad Reza Pahlavi, the last shah of Iran, was, through American and British skullduggery, imposed on Iran in 1953. His ennoblement came after then prime minister Mohammad Mosaddegh had the temerity to champion workers' rights and nationalise the country's huge oil reserves, undermining the Anglo-American exploitation — piracy dressed as international business — established by Winston Churchill on the eve of the First World War. The British and Americans hoped he might be as assertive in protecting their interests as his father was. Hardly a humanitarian, army officer Reza Shah Pahlavi brought a Tehran bakers' strike to an end by roasting the workers' leader alive in one of his ovens. That kind of decisiveness was alien to his son, who was incapable of making any decision unless he could identify someone to blame should his judgement prove inappropriate. Time and time again, as the noose of change tightened, his prevarications lost the day and cost his festering courtiers ground. It would be unfair to blame the King of Kings, a title he generously assumed in 1967, for the challenges facing his utterly corrupt country. He was supported by an American diplomatic service utterly delusional and imperceptive. The US ambassador for a lot of the Shah's reign — William Sullivan — was more interested in sustaining the lucrative circle of buying Iranian oil and encouraging the inept and insecure Shah to use a vast proportion of those revenues to buy arms from America. So detached was the American legation that fewer than a dozen of the hundreds stationed in the country could speak Farsi. This vulnerability was exacerbated by a communications process more like one from 1825. One of the often-universal themes in this wonderful book is how autocracies that outstay their welcome are often replaced by usurpers far worse than they were. Just as Russia's and China's pressure-cooker revolutions unseated rotten dynasties but replaced them with even more malignant administrations, Iran's determination to depose the Shah mixed nationalism and a medieval religious fanaticism in the person of the vile, hateful Ayatollah Ruhollah Khomeini. The legacy of that calamitous intervention remains centre stage in our volatile world. Anderson is a wonderful writer, one who winnows substance from the imagined in a way that must remind all politicians that the opportunity to resolve critical issues is not open-ended. Whether our housing crisis can gather the velocity that turned Iran rogue is an open question but it is also an increasingly pressing one. How reassuring it would be if Anderson's warning had the impact it deserves.

Trump's global tariff agenda puts Ireland's pharmaceutical industry at serious risk
Trump's global tariff agenda puts Ireland's pharmaceutical industry at serious risk

Irish Examiner

time5 hours ago

  • Irish Examiner

Trump's global tariff agenda puts Ireland's pharmaceutical industry at serious risk

The whole world is in thrall to the whims of Donald Trump's tariff agenda, as it has been since the 47th president of the United States' swearing-in last January. We've learned a few uncomfortable truths along the way. Much of the early outcry from America's allies and trading partners surrounded the lack of economic logic to the imposition of tariffs – which are effectively a tax for Americans on foreign products, in theory making them less attractive to US consumers and heightening the allure of their own domestic suppliers. Critics said that the new regime would disrupt the world economy needlessly and perhaps bring about a global recession. That may well come to pass. The problem is that in this stand-off America has the greater wherewithal in terms of raw economic power. It holds the cards as Trump himself might say. And nations worldwide are beginning to fall into line, the EU just the latest after agreeing to a blanket 15% tariff on goods and services going forward. After President of the European Commission Ursula von der Leyen and US President Donald Trump agreed the trade deal, the spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Photo:The spin is that the pain of those tariffs is worth it in order to avoid a global trade war. Also, 15% is better than 30% or worse, is the thinking. Whether that represents capitulation in the face of bullyboy tactics, given that little or nothing has been asked of the US in return, is a separate conversation. Ireland's pharmaceutical industry Here in Ireland we have a bigger problem though, and that problem is the pharmaceutical industry. That industry contributes massively to the economy here via billions of euro in corporation tax contributions, with about 90 companies employing 50,000 people in highly-paid roles. A total 30,000 of those jobs are with American firms. Should foreign pharmaceutical concerns exit Ireland the impact on the country would be catastrophic. The industry globally had pleaded with Trump for it to be exempted from any tariff regime, ostensibly for altruistic reasons – that lifesaving medicines shouldn't be subject to capricious taxation. At an EU level, the industry asked that the bloc not apply reciprocal tariffs, one wish that has at least been granted. Pfizer is one of the massive American pharmaceutical companies holding bases in Ireland, in this case Cork. File picture: Dan Linehan Oddly enough, in Trump's world of permanent grievance where everyone has been making a sucker of the United States for decades, the outsize presence the US pharmaceutical industry holds in Ireland is one situation on which he indisputably has a legitimate point. Drug prices in the US can retail for as much as five times what an EU citizen would pay. Meanwhile, American pharma firms make a pretty penny avoiding American tax by basing themselves here. Trump's protectionist agenda demands that those jobs and companies should return home. The Government has been worrying about and planning for a worst-case scenario in terms of tariffs on pharmaceuticals for months. Reaction from the pharma companies But what of the pharma industry itself? The official line from the Irish Pharmaceutical Healthcare Association (IPHA), the industry's lobby group here, is that it is reviewing the announcements coming out of Washington as and when they happen 'as key implications for the pharmaceutical sector remain uncertain'. A stance it's hard to argue with given the whole world has grown used to the haphazard nature of the Trump administration's demands. The European Federation of Pharmaceutical Industries and Associations (EFPIA) notes that tariffs are 'a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic'. It added that if the goal is to rebalance trade and ensure a 'fairer distribution' of how pharmaceutical innovation is financed, then 'there are more effective means than tariffs that would help'. Impact on pharma in Ireland The IDA, the body with prime responsibility for attracting foreign investment to Irish shores, says of the pharma implications that it 'welcomes' the deal made between Europe and the US, arguing it provides 'much-needed certainty for Irish, European and American businesses who together represent the most integrated trading relationship in the world'. 'We are very much reliant (on the US market), there's no arguing with that,' says one industry insider. Last year a massive €44bn in pharmaceutical products were exported directly from Ireland to the US. 'But when you stand back €100bn was exported globally. So half went to America, but it's not like all business went there, though it is certainly the biggest partner,' says the source. That doesn't mean that those massive American companies holding bases here – MSD, Pfizer, ELI Lilly, Johnson and Johnson etc – are about to up sticks on the back of the new tariff regime. 'They are not going to leave today or tomorrow, no. But it could definitely impact future investment decisions,' the source says. One of the problems is that a great deal of uncertainty still surrounds the 15% tariff agreement, particularly with regard to pharma. One of the Eli Lilly production buildings at its state-of-the-art facility in Dunderrow, Kinsale, Co Cork. For starters, most people concerned thought that the pharmaceutical industry wasn't to be included in the deal. Then about two hours after the deal was agreed European Commission president Ursula von der Leyen said it would be included, a point Trump appeared to back up. The following day the White House produced a 'fact sheet' describing how the new regime would work, and affirming the 15% rate for pharma. Except that the same sheet stated that the European Union would pay the tariff – which isn't how tariffs work. Then there is the Section 232 investigation which the US Department of Commerce initiated into the pharma industry in April – aiming to establish if how the pharmaceutical system worldwide currently functions impacts negatively on the US from a national security standpoint. Should the answer arrived at be a 'yes', then additional tariffs on pharma may well follow (such investigations typically take a minimum of six months to conclude, so we'll probably get an answer sometime towards the end of the year). 'Pharma plans in the long-term,' says Aidan Meagher, tax partner specialising in life sciences with consultants EY, noting that most pharma manufacturers will have been planning for this scenario for months and will have frontloaded stock into the American market, thus negating immediate impacts in the near term. He says that companies will be likely looking at 'dual sourcing' initiatives, supplying the American market from within the US itself and using Irish operations for its trade around the rest of the globe. 'Ireland needs to up its game' But Meagher says that it would be 'remiss' of Ireland, and the pharma industry here, to take a 'wait and see' approach, perhaps with the supposition that Trump's policies will last for the remaining three-and-a-half years of his term, and no longer. 'It is all about the next investment. A lot of these drugs only have patent protection for a certain life or longevity. Ireland needs to maintain investment and to incentivise the right kind of activity in terms of attracting that innovation,' he says. That means thinking outside the box in terms of tax credits for research and development, and improvements to infrastructure, particularly housing, Meagher says, areas in which we are notably lagging behind in terms of international competition. But he argues that the situation is far from a doomsday scenario. 'It's not as simple as that, it's a whole range of business factors that need to be considered – it's all about impacts for specific companies,' he says. 'It's not all necessarily doom and gloom. Companies have had plenty of time to consider this. And pharma companies are long-term thinkers. Ireland has had just two issues with the FDA (the US food and drug administration, responsible for approving new drugs) in its history. "The country has a strong reputation. These countries have invested significantly and Ireland is the owner of a lot of valuable intellectual property.' But it's certainly not a time to be complacent, Meagher argues. 'We have dropped down the competitiveness radar, and our competitors now aren't in the EU – they're in Switzerland, Singapore and the US itself. We need to be a top competitor for inward investment, and R&D and infrastructure will be critical. That is where Ireland needs to up its game.'

Indian man attacked in Dublin says his community ‘no longer feels safe' here
Indian man attacked in Dublin says his community ‘no longer feels safe' here

The Journal

time6 hours ago

  • The Journal

Indian man attacked in Dublin says his community ‘no longer feels safe' here

AN INDIAN MAN who was attacked last weekend in Dublin has said that the Indian community 'no longer feels safe' in Ireland. Santosh Yadav was assaulted at around 11.15pm on Sunday, 27 July close to Clondalkin train station. Yadav told The Journal that he was walking with his friend back to his apartment after having dinner when the assault happened. 'Suddenly there is a group of five or six teenagers, some of them on bicycles and electric scooters,' said Yadav. 'They approached from behind, I couldn't see them, and they snatched my glasses and broke them. 'They started hitting me and it all happened within three minutes or so but I was shocked, I was not aware that any such thing could happen.' Image of the broken glasses Santosh Yadav Santosh Yadav He said the group hit him all over his body. 'I was bleeding and after hitting me, they immediately left. 'My friend was screaming and she was trying to save me.' He was taken by ambulance to Blanchardstown Hospital and was there for close to 15 hours. He suffered a broken cheek bone and said that he whole face was swelled after the attack. Yadav said he feels that he was attacked 'based on my skin colour' and added that his attackers were 'white teenagers'. Santosh Yadav's face after the attack Indian Embassy warning Earlier today, the Indian Embassy in Ireland issued a safety advisory to citizens after a recent increase in physical attacks against citizens. Advertisement The Embassy said it has been in touch with the relevant authorities concerning an 'increase in physical attacks reported against Indian citizens in Ireland'. It has advised Indian citizens to 'take reasonable precautions for their personal security and avoid deserted areas, especially in odd hours'. On such assault occurred on 19 July, when a man in his 40s was assaulted by a group of youths in the Parkhill Road area of Kilnamanagh in south-west Dublin after being falsely accused of inappropriate behaviour. The man was stripped of his pants and underwear by the gang during the vicious attack. Gardaí have appealed to anyone who may have witnessed the assault to come forward and no arrests have been made so far in connection with the assault. Yadav told The Journal that it is 'very unfortunate' that the Indian Embassy had to issue the safety advisory. 'This country used to feel very safe, but now things are not that good,' said Yadav. 'The Indian Embassy came to my house and they also reported the incident, and the gardaí came to my house too. 'There are so many other incidents happening and lot of people are being targeted.' Yadav has called for 'concrete measures' to be taken to prevent these incidents and make member of the Indian community 'feel safe to walk on the streets'. Yadav said that he and others like him are 'immigrants who are here to work hard'. 'We have left our family in another country and we are here to live peacefully.' He added that in Ireland, it 'feels as though there is no law against these teenagers'. 'More is needed to ensure that these teenagers are going in a good direction.' He called for more education in school so that teenagers can learn 'human values and ethics and empathy' in order to be 'a good human being'. 'If they are doing this now, once they grow up, they will keep on doing these kind of incidents if nothing changes.' Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store